Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05140525

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

Led by Dr Sudarshan Rajagopal · Updated on 2025-10-21

15

Participants Needed

1

Research Sites

100 weeks

Total Duration

On this page

Sponsors

D

Dr Sudarshan Rajagopal

Lead Sponsor

J

Janssen Pharmaceutica N.V., Belgium

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main goal of this study is to determine the effects of combination medical therapy (Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and right ventricular (RV) function (including advanced assessments of RV-pulmonary artery (PA) coupling from invasive hemodynamics) in participants with inoperable or post-PTE residual CTEPH.

CONDITIONS

Official Title

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH)
  • Not a candidate for pulmonary thromboendarterectomy (PTE) surgery
  • Suitable anatomy and disease burden for balloon pulmonary angioplasty (BPA)
  • No prior CTEPH or pulmonary arterial hypertension (PAH)-specific medical treatments and plans to start these therapies along with BPA
  • Willing and able to give informed consent and follow study procedures and visits
Not Eligible

You will not qualify if you...

  • Moderate to severe heart disease (left ventricular ejection fraction less than 45% or severe left ventricular hypertrophy)
  • Sarcoidosis
  • Active cancer
  • Sickle cell anemia
  • Liver disease classified as Childs-Pugh class C
  • Prisoner status
  • Pregnant, planning pregnancy, or breastfeeding
  • Conditions that prevent MRI scanning (such as metal in eye, claustrophobia, or inability to lie down)
  • Allergy or contraindication to riociguat or macitentan
  • Medical or psychological conditions that increase risk or interfere with study compliance as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

Loading map...

Research Team

C

Claudia Salazar

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here